A new study published in the journal of Pediatric Dermatology revealed that treatment with dupilumab achieved effective ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

Arcutis Biotherapeutics recently reported positive topline results from its INTEGUMENT-INFANT Phase 2 trial, showing that ZORYVE cream 0.05% improved disease severity and was well tolerated in 101 ...

Russian drugmaker Binnopharm Group together with China’s Mabwell announced plans to localize the production of a monoclonal ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...

With shares down more than 40% since November, the risk-reward for Nektar Therapeutics has shifted ahead of pivotal clinical ...

More information about the 2026 AAAAI Annual Meeting can be accessed here.

Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and ...

There is a lot of interaction between pregnancy and skin changes, says Dr Nirmala M, a gynaecologist and fertility specialist ...

AbbVie Inc. targets $38B in Skyrizi and Rinvoq sales by 2030, a 3% dividend yield, and 7.7% EPS growth via acquisitions.